Stock Analysis

Estrella Immunopharma Inc Warrant Exp 09/29/202 (ESLAW)

Loading... + Investors. Track Smart Money conviction in ESLAW. See who's accumulating, reducing, or initiating positions.

Loading...
Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -2
Streak
2Q ▼
Buyers last Q
29%

Smart Money Signals — ESLAW

Based on 9 hedge funds · latest filing: 2025 Q4 · updated quarterly

📉

Selling streak — 2 quarters in a row

last 6Q
For 2 consecutive quarters, more hedge funds reduced or closed this position than added to it. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams deciding to exit.
🔻

Below peak — only 53% of 3.0Y high

53% of all-time peak
Only 9 funds hold this stock today versus a peak of 17 funds at 2024 Q2 — just 53% of the maximum. Low institutional ownership can mean the stock is out of favor, but it also means there's a large pool of potential buyers if sentiment turns.
📉

Outflows — 31% fewer funds vs a year ago

fund count last 6Q
4 fewer hedge funds hold this stock compared to a year ago (-31% decline). When institutions consistently reduce exposure, it's worth asking what they know that retail investors don't.
🔴

Heavy selling pressure — only 29% buying

2 buying5 selling
Last quarter: 5 funds sold vs only 2 buyers. This is widespread institutional distribution — not a few funds rebalancing, but a broad exit. High conviction bearish signal.
➡️

Steady new buyers — ~2 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 3 → 2 → 1 → 2. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

67% of holders stayed for 2+ years

67% conviction (2yr+) 11% medium 22% new
6 out of 9 hedge funds have held this stock for over 2 years without selling. Long-term holders are harder to shake out during market dips — they represent a stable ownership base that reduces the risk of sudden mass selling.
💎

Buying through price weakness — shares -20%, value -97%

Value
-97%
Shares
-19%
Last quarter: funds added -20% more shares while total portfolio value only changed -97%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
📊

Peak discovery — momentum slowing

0 → 3 → 2 → 1 → 2 new funds/Q
New funds entering each quarter: 3 → 2 → 1 → 2. The stock is well-known in the hedge fund world but new entries are declining. The easy phase of institutional discovery may be behind us.
📊

Mixed cohorts — 11% veterans, 22% new entrants

11% veterans 67% 1-2yr 22% new
Of 9 current holders: 1 (11%) held 2+ years, 6 held 1–2 years, 2 (22%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.

Strong quality — 22% from major AUM funds

22% from top-100 AUM funds
2 of 9 current holders rank in the top 100 by AUM. A meaningful share of the ownership base comes from the most well-resourced institutions.
2.3
out of 10
Low Exit Risk
Exit risk score 2.3/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Hedge Fund Ownership: ESLAW

How many hedge funds hold ESLAW — quarterly history vs. share price
Quarterly hedge fund ownership of ESLAW vs. share price

Market Analysis: ESLAW

View More

Analyst Price Targets

-- Low
-- High
-- Average
-- Current

Analyst Recommendations

Stock Performance

Real-time

Company Profile: ESLAW

-- --
Hedge Fund Positioning: ESLAW
Loading... + Investors

Track Smart Money conviction in ESLAW. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2025 Q4) Prior (2025 Q3) Change

Statistics: ESLAW

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --
Institutional Holders (2025 Q4)
Loading... + investors

Track Smart Money conviction in ESLAW. See who's accumulating, reducing, or initiating positions.

Investor Ownership
History
% of Portfolio Prev % Rank Conviction Avg Buy
Price
13F Score™ 3Y / 7Y Shares Mkt Value Change Change % Source Quarter Filed